




0400 6-27-01
#2

Patent Application: 09/881,322
Attorney Docket No.: PC10734ARTB

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Asst. Commissioner for Patents, U. S. Patent and Trademark Office, Washington, D.C. 20231 on this 10th day of July, 2001.

By


(Signature of person mailing)
Donna M. McLaughlin

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Frank R. Busch, et al :

APPLICATION NO.: 09/881,322 : Examiner: To Be Assigned

FILING DATE: June 14, 2001 : Group Art Unit: To Be Assigned

TITLE: THE USE OF GROWTH HORMONE :
SECRETAGOGUES TO TREAT SYSTEMIC
LUPUS ERYTHEMATOSUS AND
INFLAMMATORY BOWEL DISEASE

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.


Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 7/10/2001


Robert T. Barker
Attorney for Applicant(s)
Reg. No. 41,597

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-6067



Date Mailed: 07/10/2001 Express Mail No. _____
Application No. 09/881,322 Docket No. PC10734ARTB By dmm
Application of Frank R. Busch, et al

Entitled The Use of Growth Hormone Secretagogues to Treat Systemic Lupus Erythematosus and Inflammatory Bowel Disease

The following, due _____ in the U.S. Patent and Trademark Office, has been received there on the date stamped hereon:

- | | |
|--|---|
| <input type="checkbox"/> Specification _____ pages | <input type="checkbox"/> Amendment |
| <input type="checkbox"/> Claims _____ pages | <input type="checkbox"/> Reply |
| <input type="checkbox"/> Abstract _____ pages | <input type="checkbox"/> Notice of Appeal |
| <input type="checkbox"/> Drawing(s) _____ sheets | <input type="checkbox"/> Brief (3 copies) |
| <input type="checkbox"/> Declaration with <input type="checkbox"/> Power of Attorney | <input type="checkbox"/> Petition for Extension of Time |
| <input type="checkbox"/> Assignment & Recordation Cover Sheet | <input type="checkbox"/> Filing of Missing Parts |
| <input type="checkbox"/> Letter of Transmittal | <input type="checkbox"/> Express Mail Certificate |
| <input checked="" type="checkbox"/> Disclosure Statement <u>75</u> References | <input type="checkbox"/> Associate Power of Attorney |
| <input checked="" type="checkbox"/> Form PTO-FB-A820 | <input type="checkbox"/> Petition for Expedited Issuance for Foreign Filing License |
| <input type="checkbox"/> Issue Fee Transmittal | <input type="checkbox"/> Provisional Cover Sheet |
| <input type="checkbox"/> Fee Address Indication Form | <input type="checkbox"/> PTO-1390 (DO/EO/US) _____ pages |
| <input type="checkbox"/> Priority Document | <input type="checkbox"/> Form PTO-1050 |
| <input type="checkbox"/> Cert. of Correction under 37 CFR 1.322(a) | <input type="checkbox"/> _____ |
| <input type="checkbox"/> _____ | <input type="checkbox"/> _____ |

Box 3 of 3

INFORMATION DISCLOSURE CITATION <i>(Use separate sheets if necessary)</i>								ATTY. DOCKET NO. PC10734ARTB				SERIAL NO.09/881,322			
APPLICANT Frank R. Busch, et al								FILING DATE June 14, 2001				GROUP To Be Assigned			

U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	COUNTRY	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US	4	4	1	1	8	9	0	10/25/83	Momany	424/177	260/112.		
	US	5	4	9	2	9	1	6	02/20/96	Morriello et al	514/318	514/256		
	US	5	4	9	4	9	1	9	02/27/96	Morriello et al	514/323	514/318		
	US	5	7	2	6	3	1	9	03/10/98	Lin et al	548/253	514/19		
	US	5	5	5	9	1	2	8	09/24/96	Chakravarty et al	514/323	514/256		
	US	5	6	6	3	1	7	1	09/02/97	Chen et al	514/19	514/323		
	US	5	7	2	1	2	5	1	02/24/98	Chen et al	514/318	514/323		
	US	5	9	1	9	7	7	7	07/06/99	Hansen et al	514/183	514/212		
	US	5	8	3	0	4	3	3	11/3/98	Dean et al.	424/181	546/17		
	US	5	7	2	1	2	5	0	02/24/98	Morriello et al	514/318	514/3238		

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
								YES					NO	
	WO	8	9	0	7	1	1	0	08/10/89	International	C07K	7/00		
	WO	8	9	0	7	1	1	1	08/10/89	International	C07k	7/06		
	WO	9	3	0	4	0	8	1	03/04/93	International	C07K	7/06		
	WO	9	8	4	6	5	6	9	10/22/98	Japan	C07D	211/60		
	WO	9	8	5	1	6	8	7	11/19/98	International	C07d	47/1/10		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
		Nature, Vol. 402, pp. 656-660 (9 December 1999)												
		J. Endocrinol. Invest., 15(Suppl. 4): 45 (1992)												
		Endocrine Reviews 18(5): 621-645 (1997)												

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

